Catalyst
Slingshot members are tracking this event:
Kite Pharma (KITE) Announces the Initiation of ZUMA-2, a second Phase 2 study for KTE-C19 Assessing Patients with Relapsed or Refractory Mantle Cell Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 12, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Kte-c19, Mantle Cell Lymphoma, Phase 2 Study, Zuma-2
